IC
OVID icon

Ikarian Capital’s Ovid Therapeutics OVID Stock Holding History

Ikarian Capital’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-16,000
Closed -$92K – 252
2020
Q3 		$92K Buy
+16,000
New +$107K 0.01% 167

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Ikarian Capital's OVID Position: Q2 2026 in Review

Ikarian Capital reduced its Ovid Therapeutics (OVID) stake by 22% in Q2 2026, selling an estimated $1.61M and leaving 2,269,704 shares worth $6.11M. The position accounts for 0.66% of the portfolio, ranked #44.

Ikarian Capital first reported a position in OVID in Q4 2019 and has held it in 12 quarters since. The position peaked at $6.43M in Q1 2026. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Ikarian Capital held 2,269,704 shares of Ovid Therapeutics worth $6.11M as of Q2 2026.
  • Ikarian Capital sold 625,000 Ovid Therapeutics shares in Q2 2026, an estimated $1.61M.
  • Ovid Therapeutics made up 0.66% of Ikarian Capital's portfolio in Q2 2026, its #44 holding.
  • Ikarian Capital first reported a position in Ovid Therapeutics in Q4 2019 and has held it in 12 quarters since.
  • Ikarian Capital's Ovid Therapeutics position peaked at $6.43M in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.